- IN₹1.07tn
- IN₹973.06bn
- IN₹281.63bn
Focus: Lilly, Novo lock horns in India's obesity drug race
Brief: Cipla - Pfizer & Cipla Announce Exclusive Marketing, Distribution Partnership For Select Brands In India
Brief: Cipla Launches Yurpeak For Obesity And Type 2 Diabetes
Brief: Venus Remedies Receives Final 110 Mln Rupees Payment From Cipla
Novo Nordisk gears up for December Ozempic launch in India, sources say (updated)
Novo Nordisk gears up for December Ozempic launch in India, sources say
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
Aurobindo Pharma's profit rises on steady domestic demand
India's Cipla extends losses on trimming FY26 margin outlook
Brief: Cipla Says Umang Vohra To Step Down As MD & GCEO
Brief: Cipla GCEO Vohra Says Co Will Take Eli Lilly's Yurpeak (Mounjaro) Into Tier 2, Tier 3 Markets With Partnership
India's Cipla falls after global CEO steps down
India's Cipla global CEO Umang Vohra to step down
Brief: Cipla Says By CY 2026 Expect To Launch 4 Major Respiratory Assets
Indian drugmaker Cipla beats profit view on steady respiratory drugs demand (updated)
Indian drugmaker Cipla beats profit view on steady respiratory drugs demand
Brief: Cipla Q2 Consol Net Profit 13.51 Bln Rupees IBES EST. 13.47 Bln Rupees
Indian drugmaker Cipla drops ahead of quarterly results
Eli Lilly rise after reaching distribution deal with Indian drugmaker Cipla